文献速递肝病消化道肿瘤与早癌

肝细胞癌的联合免疫治疗

Combination immunotherapy for hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2023-03-16

单药免疫检查点抑制剂(ICI)在晚期肝细胞癌(HCC)中客观缓解率为15-20%,多无显著总生存(OS)获益,约30%的HCC对ICI存在原发耐药。本综述总结了ICI联合抗血管生成药物、两种ICI联合、ICI联合酪氨酸激酶抑制剂或抗CTLA-4抗体的科学依据与临床数据。IMbrave150试验阳性结果促成阿替利珠单抗-贝伐珠单抗获批,HIMALAYA试验显示度伐利尤单抗-替西木单抗(STRIDE方案)优于索拉非尼。

要点

  • 单药ICI在晚期HCC客观缓解率15-20%,多数无显著OS获益,约30%原发耐药。
  • IMbrave150试验阳性结果促成阿替利珠单抗-贝伐珠单抗获批,为索拉非尼获批后首个一线显示生存获益的方案。
  • HIMALAYA试验显示度伐利尤单抗-替西木单抗(STRIDE方案)优于索拉非尼,确立新一线选择。

核心结论

  • 联合免疫治疗是晚期HCC的重要治疗策略,IMbrave150和HIMALAYA试验分别确立了阿替利珠单抗-贝伐珠单抗和度伐利尤单抗-替西木单抗(STRIDE方案)的一线地位。
  • ICI联合酪氨酸激酶抑制剂结果不一致,仅一项III期试验显示OS获益。
  • 治疗选择与序贯、生物标志物鉴定、联合局部治疗及新型免疫药物开发等问题有待未来研究解决。

研究设计与样本

  • 本文为综述,总结晚期HCC联合免疫治疗的科学依据和现有临床数据。

主要发现

  • 单药ICI在晚期HCC中客观缓解率为15-20%,多无显著OS获益,约30%的HCC对ICI存在原发耐药。
  • 篮子试验(含HCC队列)和早期研究测试了ICI联合抗血管生成药物及两种不同ICI的联合。
  • IMbrave150试验阳性结果促成阿替利珠单抗-贝伐珠单抗获批,为索拉非尼获批后首个一线显示生存获益的方案。
  • HIMALAYA试验显示度伐利尤单抗-替西木单抗(STRIDE方案)优于索拉非尼。
  • ICI联合酪氨酸激酶抑制剂结果不一致,仅一项III期试验显示OS获益。

关键数值与推荐

  • 单药ICI在晚期HCC客观缓解率15-20%,约30%的HCC对ICI存在原发耐药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Single-agent immune checkpoint inhibitors (ICIs) have been tested in patients with advanced hepatocellular carcinoma (HCC), leading to objective response rates of 15-20%, mostly without a significant overall survival (OS) benefit. Furthermore, approximately 30% of HCC exhibits intrinsic resistance to ICIs. In the absence of predictive biomarkers to identify patients likely to benefit most from immunotherapy, research has moved to exploring combinations with potential activity in broader patient populations. Basket trials, including cohorts of patients with HCC, and early phase studies tested the combination of ICIs with anti-angiogenic agents as well as the combination of two different ICIs. The promising results that were achieved provided the rationale for the following phase III trials, which tested the combination of anti-PD-1/PD-L1 antibodies with bevacizumab, or tyrosine kinase inhibitors, or anti-CTLA-4 antibodies. Positive results from the IMbrave150 trial led to the practice-changing approval of atezolizumab-bevacizumab, the first regimen to demonstrate improved survival in the front-line setting since the approval of sorafenib. More recently, the HIMALAYA trial demonstrated the superiority of durvalumab-tremelimumab (STRIDE regimen) over sorafenib, establishing a new first-line option. In contrast, inconsistent results have been achieved with combinations of ICIs and tyrosine kinase inhibitors, with only one phase III trial showing an OS benefit. The rapid evolution of the therapeutic landscape for patients with advanced HCC has left many unanswered questions that will need to be addressed by future research. These include the choice and sequencing of treatments, identification of biomarkers, combinations with locoregional therapies, and development of new immunotherapy agents. This review summarises the scientific rationale and available clinical data for combination immunotherapy in advanced HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Rimassa L, Finn RS, Sangro B, et al. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023. PMID: 36933770. doi:10.1016/j.jhep.2023.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。